Thus, we believe that the dual-functional conjugates, which consist of the PD-L1-targeted polypeptide that renders both the tumor-specific drug delivery and inhibitory PD-1/PD-L1 immune checkpoint inhibition, and a cytotoxic agent that kills tumor cells once reaching tumor tissues, represents a promising therapeutic option for colon cancer. The gene discussed is CD274; the disease is neoplasm.